1. Market Research
  2. > Pharmaceutical Market Trends
CDK9 inhibitor - Pipeline Insight, 2022

CDK9 inhibitor - Pipeline Insight, 2022

  • January 2022
  • 60 pages
  • ID: 6222895
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Understanding

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Overview
CDK9 is not a typical Cdc2-like kinase. It does not act in cell-cycle regulation processes; rather, it acts in differentiation processes. It is the catalytic subunit of P-TEFb that, in association with Cyclin T, has the ability to phosphorilate the CTD substrate of RNA polymerase II and reach the RNA transcription elongation. There are 2 isoforms of the CDK9 protein: the major 42 kDa CDK9 isoform, and the minor 55 kDa isoform.

Function –CDK9 is not a typical Cdc2-like kinase. It does not act in cell-cycle regulation processes; rather, it acts in differentiation processes. It is the catalytic subunit of P-TEFb that, in association with Cyclin T, has the ability to phosphorilate the CTD substrate of RNA polymerase II and reach the RNA transcription elongation.Although there are other cyclin-dependent kinases that are capable of phosphorilating the CTD, the only one that activates gene expression in a catalyst manner is CDK9.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitors- CDK9 is one of the major Pol II-directed kinases of P-TEFb. A number of small-molecule inhibitors of CDK9 kinase activity directed to the ATP-binding pocket have been developed and tested. A number of natural compounds have been identified as non-selective inhibitors of CDKs. The bis-indoles indirubins were the first human-used compounds to be identified as CDK inhibitors. CDK9 Blockade is A Potential Treatment For Pediatric Soft Tissue Sarcomas.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Emerging Drugs Chapters
This segment of the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Emerging Drugs
• Dinaciclib: Merck & Co
Dinaciclib (SCH 727965) is a small molecule inhibitor of cyclin-dependent kinases. Dinaciclib demostrates potent and selective inhibition of CDK2, CDK5, CDK1, and CDK9 activity. Dinaciclib inhibits cell cycle progression and proliferation in various tumor cell lines in vitro. Dinaciclib is a product of a drug discovery collaboration between Pharmacopeia (later Ligand Pharmaceuticals) and Schering-Plough (later Merck & Co.). The drug is currently in phase 3 of clinical trials for the treatment of Chronic lymphocytic leukaemia.

• KB-0742: Kronos Bio
KB-0742 is a selective, orally bioavailable inhibitor of CDK9, a global regulator of transcription and a critical node in the oncogenic TRN resulting from MYC overexpression. MYC is a well-known transcription factor and cancer driver that is dysregulated in a significant proportion of human cancers, often via genomic copy number gain, or amplification. The drug is currently in phase 1/2 of clinical trials for the treatment of Solid tumours.

• Alvocidib: Sumitomo Dainippon Pharma Oncology
Alvocidib is an investigational, intravenously administered, small molecule cyclin-dependent kinase 9 (CDK9) inhibitor.Inhibiting CDK9 is thought to downregulate the transcription of target genes, including myeloid cell leukemia 1 (MCL-1), reducing leukemic blast viability in MCL-1–dependent, hematologic malignancies. The drug is currently in phase 2 of clinical trials for the treatment of acute myeloid leukemia.

Further product details are provided in the report……..

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Cyclin-Dependent Kinase 9 (CDK9) Inhibitor
There are approx. 15+ key companies which are developing the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor. The companies which have their Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

• Phases
This report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cyclin-Dependent Kinase 9 (CDK9) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Cyclin-Dependent Kinase 9 (CDK9) Inhibitor R&D. The therapies under development are focused on novel approaches for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Report Insights
• Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs?
• How many Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Merck & Co
• Kronos Bio
• Sumitomo Dainippon Pharma Oncology
• AstraZeneca
• Kino Pharma
• Cyclacel Pharmaceuticals
• Bayer
• MEI Pharma
• Syros Pharmaceuticals
• BioTheryX
• Le Sun Pharmaceuticals
• NeoSome Life Sciences
• Adastra Pharmaceuticals/S*Bio
• Virostatics
• GenFleet Therapeutics
• ASINEX

Key Products
• Dinaciclib
• KB-0742
• Alvocidib
• AZD 4573
• TP 1287
• FIT 039
• BAY 1251152
• Seliciclib
• Fadraciclib
• Voruciclib
• SY 5609
• BTX A51
• Research programme: cancer therapeutics
• NEOS 518
• Zotiraciclib
• Research programme: anticancer therapeutics
• Research programme: cyclin-dependant kinases
• GFH 009

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • $ 2000
  • April 2022
  • 127 pages

Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Cough - Drugs In Development, ...

  • World
  • China
  • Pharmaceutical
  • Therapy
  • Industry analysis

ref:plp2021

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on